相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。The continuing quest for better subcutaneously administered prandial insulins: a review of recent developments and potential clinical implications
David R. Owens et al.
DIABETES OBESITY & METABOLISM (2020)
Ultrarapid lispro lowers postprandial glucose and more closely matches normal physiological glucose response compared to other rapid insulin analogues: A phase 1 randomized, crossover study
Tim Heise et al.
DIABETES OBESITY & METABOLISM (2020)
The Evolution of Insulin and How it Informs Therapy and Treatment Choices
Irl B. Hirsch et al.
ENDOCRINE REVIEWS (2020)
105-LB: Evening Oral Insulin (ORMD-0801) Glycemic Effects in Uncontrolled T2DM Patients
ROY ELDOR et al.
DIABETES (2020)
Once-Weekly Insulin for Type 2 Diabetes without Previous Insulin Treatment
Julio Rosenstock et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Digital diabetes: Perspectives for diabetes prevention, management and research
G. Fagherazzi et al.
DIABETES & METABOLISM (2019)
ENHANZE((R)) drug delivery technology: a novel approach to subcutaneous administration using recombinant human hyaluronidase 20
Kenneth W. Locke et al.
DRUG DELIVERY (2019)
Hepatic Insulin Clearance: Mechanism and Physiology
Sonia M. Najjar et al.
PHYSIOLOGY (2019)
Divergent Hypoglycemic Effects of Hepatic-Directed Prandial Insulin: A 6-Month Phase 2b Study in Type 1 Diabetes
David Klonaff et al.
DIABETES CARE (2019)
An ultra-stable single-chain insulin analog resists thermal inactivation and exhibits biological signaling duration equivalent to the native protein
Michael D. Glidden et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2018)
Insulin Access and Affordability Working Group: Conclusions and Recommendations
William T. Cefalu et al.
DIABETES CARE (2018)
Ultra-rapid BioChaperone Lispro improves postprandial blood glucose excursions vs insulin lispro in a 14-day crossover treatment study in people with type 1 diabetes
Grit Andersen et al.
DIABETES OBESITY & METABOLISM (2018)
Lessons for modern insulin development
R. Herring et al.
DIABETIC MEDICINE (2018)
Artificial pancreas treatment for outpatients with type 1 diabetes: systematic review and meta-analysis
Eleni Bekiari et al.
BMJ-BRITISH MEDICAL JOURNAL (2018)
Artificial pancreas treatment for outpatients with type 1 diabetes: systematic review and meta-analysis
Eleni Bekiari et al.
BMJ-BRITISH MEDICAL JOURNAL (2018)
Identification of barriers to insulin therapy and approaches to overcoming them
David Russell-Jones et al.
DIABETES OBESITY & METABOLISM (2018)
How Can a Good Idea Fail? Basal Insulin Peglispro [LY2605541] for the Treatment of Type 2 Diabetes
Araceli Munoz-Garach et al.
DIABETES THERAPY (2017)
How Can a Good Idea Fail? Basal Insulin Peglispro [LY2605541] for the Treatment of Type 2 Diabetes
Araceli Munoz-Garach et al.
DIABETES THERAPY (2017)
Efficacy and Safety of Degludec versus Glargine in Type 2 Diabetes
Steven P. Marso et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Development of glucose-responsive smart' insulin systems
Nischay K. Rege et al.
CURRENT OPINION IN ENDOCRINOLOGY DIABETES AND OBESITY (2017)
Rational Design of Glucose-Responsive Insulin Using Pharmacokinetic Modeling
Naveed A. Bakh et al.
ADVANCED HEALTHCARE MATERIALS (2017)
Effect of artificial pancreas systems on glycaemic control in patients with type 1 diabetes: a systematic review and meta-analysis of outpatient randomised controlled trials
Alanna Weisman et al.
LANCET DIABETES & ENDOCRINOLOGY (2017)
Randomized double-blind clinical trial comparing basal insulin peglispro and insulin glargine, in combination with prandial insulin lispro, in patients with type 2 diabetes: IMAGINE 4
T. Blevins et al.
DIABETES OBESITY & METABOLISM (2016)
Basal insulin peglispro versus insulin glargine in insulin-naive type 2 diabetes: IMAGINE 2 randomized trial
M. J. Davies et al.
DIABETES OBESITY & METABOLISM (2016)
Oral delivery of insulin for treatment of diabetes: status quo, challenges and opportunities
Chun Y. Wong et al.
JOURNAL OF PHARMACY AND PHARMACOLOGY (2016)
Glycemic Variability and Diabetes Complications: Does It Matter? Of Course It Does!
Irl B. Hirsch
DIABETES CARE (2015)
Faster-acting insulin aspart: earlier onset of appearance and greater early pharmacokinetic and pharmacodynamic effects than insulin aspart
T. Heise et al.
DIABETES OBESITY & METABOLISM (2015)
New forms of insulin and insulin therapies for the treatment of type 2 diabetes
Avivit Cahn et al.
LANCET DIABETES & ENDOCRINOLOGY (2015)
Comparison of dual-hormone artificial pancreas, single-hormone artificial pancreas, and conventional insulin pump therapy for glycaemic control in patients with type 1 diabetes: an open-label randomised controlled crossover trial
Ahmad Haidar et al.
LANCET DIABETES & ENDOCRINOLOGY (2015)
New Insulin Glargine 300 Units/mL Versus Glargine 100 Units/mL in People With Type 2 Diabetes Using Basal and Mealtime Insulin: Glucose Control and Hypoglycemia in a 6-Month Randomized Controlled Trial (EDITION 1)
Matthew C. Riddle et al.
DIABETES CARE (2014)
PEGylated insulin Lispro, (LY2605541)-a new basal insulin analogue
T. M. Caparrotta et al.
DIABETES OBESITY & METABOLISM (2014)
The pharmacokinetics and pharmacodynamics of rapid-acting insulin analogues and their clinical consequences
P. D. Home
DIABETES OBESITY & METABOLISM (2012)
Oral insulin - a review of current status
Harish Iyer et al.
DIABETES OBESITY & METABOLISM (2010)
分享论文
